# Latigo Biotherapeutics, Inc.: financial statements, quarterly

LTGO · Nasdaq · CIK 2056611 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ltgo.md) · [Financials](/companies/ltgo/financials.md) · [Filings](/companies/ltgo/filings.md) · [Insiders](/companies/ltgo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ltgo/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | [22.9](/filings/0001193125-26-381969.md) | not reported | [21.2](/filings/0001193125-26-381969.md) |
| Operating income | $m | not reported | [(25.7)](/filings/0001193125-26-381969.md) | not reported | [(25.8)](/filings/0001193125-26-381969.md) |
| Interest expense | $m | not reported | [0.0](/filings/0001193125-26-381969.md) | not reported | [0.3](/filings/0001193125-26-381969.md) |
| Income tax | $m | not reported | [0.0](/filings/0001193125-26-381969.md) | not reported | [0.0](/filings/0001193125-26-381969.md) |
| Net income | $m | [(21.0)](/filings/0001193125-26-381969.md) | [(25.8)](/filings/0001193125-26-381969.md) | [(23.0)](/filings/0001193125-26-381969.md) | [(25.8)](/filings/0001193125-26-381969.md) |
| Diluted EPS | $ per share | not reported | [(36.52)](/filings/0001193125-26-381969.md) | not reported | [(27.59)](/filings/0001193125-26-381969.md) |
| Basic EPS | $ per share | not reported | [(36.52)](/filings/0001193125-26-381969.md) | not reported | [(27.59)](/filings/0001193125-26-381969.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [69.4](/filings/0001193125-26-381969.md) | not reported | [55.0](/filings/0001193125-26-381969.md) |
| Current assets | $m | not reported | not reported | not reported | [73.8](/filings/0001193125-26-381969.md) | not reported | [59.2](/filings/0001193125-26-381969.md) |
| Total assets | $m | not reported | not reported | not reported | [75.5](/filings/0001193125-26-381969.md) | not reported | [64.8](/filings/0001193125-26-381969.md) |
| Current liabilities | $m | not reported | not reported | not reported | [18.4](/filings/0001193125-26-381969.md) | not reported | [51.6](/filings/0001193125-26-381969.md) |
| Total liabilities | $m | not reported | not reported | not reported | [18.6](/filings/0001193125-26-381969.md) | not reported | [52.3](/filings/0001193125-26-381969.md) |
| Shareholders' equity | $m | [(130)](/filings/0001193125-26-381969.md) | [(149)](/filings/0001193125-26-381969.md) | [(173)](/filings/0001193125-26-381969.md) | [(232)](/filings/0001193125-26-381969.md) | [(253)](/filings/0001193125-26-381969.md) | [(276)](/filings/0001193125-26-381969.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Shares

| Line item | Unit | period not labelled (2025-06-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [707](/filings/0001193125-26-381969.md) | [935](/filings/0001193125-26-381969.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 66,299,347 at 2026-09-01, from the cover of the [10-Q filed 2026-09-03](/filings/0001193125-26-381969.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.